The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Inflammation-associated cancer: NF-κB is the lynchpin
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
Self-citationHayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
The two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
El-Omar, E. M., Carrington, M., Chow, W.-H., McColl, K. E. L., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C.-C., Rothman, N., et al. (2000) · Nature · doi:10.1038/35006081 · Cited by 2,366
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation
Viatour, P., Merville, M.-P., Bours, V., & Chariot, A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.009 · Cited by 1,496
Inferences, questions and possibilities in Toll-like receptor signalling
Beutler, B. (2004) · Nature · doi:10.1038/nature02761 · Cited by 1,466
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
TIRAP: an adapter molecule in the Toll signaling pathway
Horng, T., Barton, G. M., & Medzhitov, R. (2001) · Nature Immunology · doi:10.1038/ni0901-835 · Cited by 969
Anti-inflammatory lipid mediators and insights into the resolution of inflammation
Lawrence, T., Willoughby, D. A., & Gilroy, D. W. (2002) · Nature Reviews Immunology · doi:10.1038/nri915 · Cited by 862
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar-Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 851
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Possible new role for NF-κB in the resolution of inflammation
Lawrence, T., Gilroy, D. W., Colville-Nash, P. R., & Willoughby, D. A. (2001) · Nature Medicine · doi:10.1038/nm1201-1291 · Cited by 749
Inflammation and necrosis promote tumour growth
Vakkila, J., & Lotze, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1415 · Cited by 690
May, M. J., D'Acquisto, F., Madge, L. A., Glöckner, J., Pober, J. S., & Ghosh, S. (2000) · Science · doi:10.1126/science.289.5484.1550 · Cited by 680
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Luo, J.-L., Maeda, S., Hsu, L.-C., Yagita, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 603
Nissen, R. M., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.827900 · Cited by 559
NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia
Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y., et al. (2003) · Nature · doi:10.1038/nature01283 · Cited by 535
Chen, L.-W., Egan, L., Li, Z.-W., Greten, F. R., Kagnoff, M. F., & Karin, M. (2003) · Nature Medicine · doi:10.1038/nm849 · Cited by 483
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2
Pasparakis, M., Courtois, G., Hafner, M., Schmidt-Supprian, M., Nenci, A., Toksoy, A., Krampert, M., Goebeler, M., Gillitzer, R., Israel, A., et al. (2002) · Nature · doi:10.1038/nature00820 · Cited by 470
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
Jiang, Y., Genant, H. K., Watt, I., Cobby, M., Bresnihan, B., Aitchison, R., & McCabe, D. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p · Cited by 399
Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G. L., Loar, A., Rodabough, R. J., White, E., & McTiernan, A. (2003) · PubMed · Cited by 371
Colorectal Cancer and Nonsteroidal Anti-inflammatory Drugs
Smalley, W. E., & DuBois, R. N. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60067-8 · Cited by 356
Derangement of immune responses by myeloid suppressor cells
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., & Bronte, V. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0443-2 · Cited by 335
Scheinfeld, N. S. (2004) · Journal of Dermatological Treatment · doi:10.1080/09546630410017275 · Cited by 316
Ikappa Balpha -independent downregulation of NF-kappa B activity by glucocorticoid receptor
Heck, S. (1997) · The EMBO Journal · doi:10.1093/emboj/16.15.4698 · Cited by 295
Inhibition of Nuclear Factor Kappa B (NF-B):: An Emerging Theme in Anti-Inflammatory Therapies
D'Acquisto, F. (2002) · Molecular Interventions · doi:10.1124/mi.2.1.22 · Cited by 237
Activation of Transcription Factor NF-κB Requires ELKS, an IκB Kinase Regulatory Subunit
Sigala, J. L. D., Bottero, V., Young, D. B., Shevchenko, A., Mercurio, F., & Verma, I. M. (2004) · Science · doi:10.1126/science.1098387 · Cited by 219
Self-citationCorrection: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer
El-Omar, E. M., Carrington, M., Chow, W.-H., McColl, K. E. L., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C.-C., Rothman, N., et al. (2001) · Nature · doi:10.1038/35083631 · Cited by 217
Regional analysis of p53 mutations in rheumatoid arthritis synovium
Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J., & Firestein, G. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152333199 · Cited by 214
Shishodia, S., Koul, D., & Aggarwal, B. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2011 · Cited by 185
Historical review: Cytokines as therapeutics and targets of therapeutics
Vilček, J., & Feldmann, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.011 · Cited by 185
Torgerson, T. R., Colosia, A. D., Donahue, J. P., Lin, Y. Z., & Hawiger, J. (1998) · PubMed · Cited by 180
Takada, Y., Singh, S., & Aggarwal, B. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311192200 · Cited by 179
NF-κB in cancer—a friend turned foe
Ravi, R. K., & Bedi, A. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.003 · Cited by 174
Cytokines and anti-cytokine biologicals in autoimmunity: present and future
Andreakos, E. T., Foxwell, B. M., Brennan, F. M., Maini, R. N., & Feldmann, M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00018-7 · Cited by 171
Torgerson, T. R., Colosia, A. D., Donahue, J. P., Lin, Y.-Z., & Hawiger, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6084 · Cited by 167
Characterization of the IκB-kinase NEMO Binding Domain
May, M. J., Marienfeld, R. B., & Ghosh, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206494200 · Cited by 152
Desmet, C. J., Gosset, P., Pajak, B., Cataldo, D. D., Bentires‐Alj, M., Lekeux, P. M., & Bureau, F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5766 · Cited by 138
Tumor necrosis factor-? in the pathogenesis and treatment of cancer
ANDERSON, G. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.04.004 · Cited by 138
p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids
Ito, K., Jazrawi, E., Cosío, B. G., Barnes, P. J., & Adcock, I. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103604200 · Cited by 136
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention
Kısmet, K., Akay, M. T., Abbasoğlu, O., & Ercan, A. (2004) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2003.12.005 · Cited by 131
Doucas, V., Shi, Y., Miyamoto, S., West, A., Verma, I., & Evans, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413297 · Cited by 125
Self-citationKolenko, V. M., Bloom, T., Rayman, P. A., Bukowski, R. M., Hsi, E. D., & Finke, J. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.590 · Cited by 107
Kolenko, V. M., Bloom, T., Rayman, P. A., Bukowski, R. M., Hsi, E. D., & Finke, J. H. (1999) · PubMed · Cited by 102
Guo, J., Verma, U. N., Gaynor, R. B., Frenkel, E. P., & Becerra, C. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0366 · Cited by 93
Molecular therapy to inhibit NFκB activation by transcription factor decoy oligonucleotides
Morishita, R., Tomita, N., Kaneda, Y., et al. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.008 · Cited by 87
Deregulation of NF-κB and its upstream kinases in cancer
Sun, S.-C., & Xiao, G. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023733231406 · Cited by 83
Mochizuki, Y., Nakanishi, H., Kodera, Y., et al. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000017181.01474.35 · Cited by 78
The v‐rel oncogene promotes malignant T‐cell leukemia/lymphoma in transgenic mice.
Carrasco, D. R., Rizzo, C. A., Dorfman, K. S., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00733.x · Cited by 76
Thalidomide as an anti‐cancer agent
Kumar, S. K., Witzig, T. E., & Rajkumar, S. V. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00184.x · Cited by 72
Targeting cytokines to inflammation sites
Adams, G., Vessillier, S., Dreja, H. S., & Chernajovsky, Y. (2003) · Nature Biotechnology · doi:10.1038/nbt888 · Cited by 64
Agou, F., Courtois, G., Chiaravalli, J., Baleux, F., Coïc, Y., Traincard, F., Israël, A., & Véron, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406423200 · Cited by 62
The role of Rel/NF-κB transcription factors in B lymphocyte survival
Gerondakis, S., & Strasser, A. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(03)00036-8 · Cited by 59
Inhibition of NF-κB mediated inflammation by siRNA expressed by recombinant adeno-associated virus
Pinkenburg, O., Platz, J., Beißwenger, C., Vogelmeier, C. F., & Bals, R. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.04.007 · Cited by 38
Of mice and men: Meeting on the biology and pathology of NF-κB
Ben‐Neriah, Y., & Schmitz, M. L. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400187 · Cited by 23
Immunoregulatory Genes and Immunosuppression by Glucocorticoids
Auphan‐Anezin, N., DiDonato, J. A., Helmberg, A., Rosette, C., & Karin, M. (1997) · Archives of toxicology. Supplement · doi:10.1007/978-3-642-60682-3_8 · Cited by 21
Targeted gene therapy: frontiers in the development of ?smart drugs?
Tarner, I. H. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.04.001 · Cited by 19
Cited by
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
Oxidative stress and cancer: Have we moved forward?
Halliwell, B. (2007) · Biochemical Journal · doi:10.1042/bj20061131 · Cited by 1,302
Metadata
- Authors
- Li, Q., Withoff, S., & Verma, I. M.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 26
- Issue
- 6
- Pages
- 318-325
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W1980300702
- Cited by
- 268
- References
- 74
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.